Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rifaximin - Alfasigma

Drug Profile

Rifaximin - Alfasigma

Alternative Names: Dermodis; EIR formulation of rifaximin - Salix Pharmaceuticals; Flonorm; L-105; Lumenax; Normix; RedActive®; Rifacol; Rifaxidin®; Rifaximin soluble solid dispersion tablet; Rifaximin SSD/next generation formulation; Rifaximin-a 550mg; rifaximin-alpha; Rifxima; Spiraxin; Targaxan 550; Tixtar; Xifaxan; Xifaxan 550mg; XIFAXAN550; Xifaxanta; Zaxine

Latest Information Update: 12 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alfa Wassermann SpA
  • Developer Alfa Wassermann SpA; ASKA Pharmaceutical; Lupin; Norgine; Salix Pharmaceuticals
  • Class Antibacterials; Antidiarrhoeals; Hepatoprotectants; Irritable bowel syndrome therapies; Rifamycins; Small molecules
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatic encephalopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diverticulitis; Hepatic encephalopathy; Hyperammonaemia; Intestinal infections; Irritable bowel syndrome; Skin and soft tissue infections; Traveller's diarrhoea
  • Phase III Crohn's disease
  • Phase II Liver disorders
  • Discontinued Bacterial vaginosis; Clostridium difficile infections; Pouchitis; Shigella infections

Most Recent Events

  • 06 Dec 2018 Launched for Irritable bowel syndrome in Canada (PO)
  • 06 Dec 2018 Preregistration for Irritable bowel syndrome in Canada (PO) before December 2018
  • 06 Dec 2018 Registered for Irritable bowel syndrome in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top